E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

Eur J Paediatr Neurol. 2020 Nov:29:22-31. doi: 10.1016/j.ejpn.2020.11.001. Epub 2020 Nov 7.

Abstract

A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).

Keywords: Acquired demyelinating syndromes; Biomarkers; Cell based assays; Children; Myelin-oligodendrocyte glycoprotein; Neurofilament.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Autoantigens / immunology
  • Biomarkers / analysis*
  • Child
  • Demyelinating Autoimmune Diseases, CNS / diagnosis*
  • Demyelinating Autoimmune Diseases, CNS / immunology*
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein / immunology*

Substances

  • Autoantibodies
  • Autoantigens
  • Biomarkers
  • Myelin-Oligodendrocyte Glycoprotein